- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02350842
Triple-site Biventricular Stimulation in the Optimization of CRT (TRIUMPH-CRT)
Triple-site Biventricular Stimulation in the Optimization of Cardiac Resynchronization Therapy (CRT)
Cardiac resynchronization is a recommended therapy for patients with advanced heart failure, under optimized medical treatment with reduced left ventricular ejection fraction and prolonged QRS, nevertheless, still 30% of the population do not respond to standard biventricular implantation.
Non-response can be explained by a combination of factors including sub-optimal patient selection, placement of the pacing lead over a zone of slow conduction, insufficient correction of mechanical dyssynchrony including sub-optimal lead implantation. Few data distinguish true non-responders from patients in which effective resynchronization was not delivered through standard biventricular implantation.
Triple-site cardiac resynchronization pacing (stimulation at three ventricular sites) has been proposed to improve synchrony and thus the response rate in (Cardiac Resynchronisation Therapy) CRT recipients.
Study Overview
Status
Conditions
Detailed Description
The frequent failure of CRT in non-Left Bundle Branch Block (non-LBBB) patients is suspected to be due to more complex and heterogeneous forms of electrical/mechanical dyssynchronies needing more complex and individualized pacing configurations to be corrected.
Acute studies during implant show that standard biventricular pacing provides optimal mechanical improvement only in a minority of patients. In a peri-operative echo-guided leads placement procedure most of non-improved patients could be successfully mechanically resynchronized. A significant number of patients required optimized placement of right ventricular (RV) lead and/or triple-site configurations.
These studies led to the hypothesis that more complex and individualized pacing configurations (Triple-site biventricular) might increase the number of responders to CRT.
To assess this hypothesis, this study will be conducted in Class II-ambulatory IV patients indicated for CRT with wide QRS (≥ 140 ms) and non-LBBB. Patients will be randomized in a 1:1 configuration:
- Standard biventricular pacing (1 right ventricular/1 left ventricular (1RV/1LV)) through classical implantation procedure without peri-operative optimization
- Triple-site biventricular pacing with individual optimization of the placement of the third lead by peri-operative echo guidance.
The objective of the optimization process is to improve LV efficiency and to decrease the left pre-ejection interval (LPEI, defined as the time interval between the onset of QRS and the onset of LV ejection) as much as possible compared with a standard biventricular configuration by moving a second right ventricular lead at different locations.
LPEI is simple to measure, with good inter- and intra-observer reproducibility and its utility has previously been strongly suggested.
Reduction in LPEI results in decreased duration of ventricular systole and is associated with improved LV filling and reduced interventricular delay.
The primary objective of this study is to demonstrate that individually optimized, triple-site biventricular pacing is superior to standard biventricular pacing in reverse ventricular modeling as demonstrated by Echo Left Ventricle End-Systolic Volume (LVESV) at 1 year in patients with non-LBBB morphology without increasing the risk of serious procedure and/or device related adverse events at 30 days.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Amiens, France, 80054
- CHRU Hopital Sud
-
Avignon, France, 84082
- Clinique Rhône Durance
-
Besançon, France, 25030
- Hopital Jean Minjoz Besancon
-
Brest, France, 29609
- CHRU Brest
-
Paris, France, 75614
- Groupe Hospitalier Paris Saint-Joseph
-
Poitiers, France, 86021
- CHU Poitiers
-
Rouen, France, 76031
- CHU Hôpital Charles Nicolle
-
Toulouse, France, 31400
- CHU Toulouse, Hôpital Rangueil
-
-
-
-
-
Kiel, Germany, D-24105
- Universitaetsklinikum Schleswig Holstein
-
-
-
-
-
Bergamo, Italy, 24125
- Humanitas Cliniche Gavazzeni spa
-
-
-
-
-
Zwolle, Netherlands, 8025AB
- Isala Zwolle
-
-
-
-
-
Lisbon, Portugal, 1169-024
- CHCL - Hospital Santa Marta
-
-
-
-
-
Barcelona, Spain, 8025
- Hospital de la Santa Creu i Sant Pau
-
Valencia, Spain, 46009
- Hospital Universitario La Fe
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years
- Stable heart failure with New York Heart Association (NYHA) functional class II, III or ambulatory IV
- Stable optimized medical regimen according to medical guidelines (No change in heart failure medication for at least 1 month prior to enrollment)
- Left ventricular ejection fraction (LVEF) ≤ 35%
- Intrinsic QRS duration ≥ 140 msec
- Non-typical left bundle branch block (LBBB) morphology on 12-lead surface ECG
- Signed and dated informed consent
Exclusion Criteria:
- Typical LBBB according to Strauss criteria
- Unstable heart failure
- Permanent or long-lasting persistent Atrial Fibrillation
- Unstable angina, acute Myocardial Infarction (MI), Coronary Artery Bypass-Grafting (CABG), or Percutaneous Transluminal Coronary Angioplasty (PTCA) within 90 days prior to enrollment (intervention)
- Conventional pacemaker indication
- Previous implant with a pacemaker or an Implantable Cardioverter-Defibrillator (ICD)
- Renal Failure (Glomerular filtration rate (GFR) < 30 ml/min/1.73m2)
- Pregnant women
- Already included in another clinical study that could confound the results of this study
- Life expectancy < 12 months
- Mechanical heart valve or indication for valve repair or replacement
- Recent Cerebro-Vascular Accident (CVA) or Transient Ischemic Attack (TIA) (within the previous 3 months)
- Heart transplant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Triple-site biventricular pacing
Triple-site biventricular pacing with individual optimization of the placement of the third lead by peri-operative echo guidance.
Devices used will be the Sorin, locally approved and commercially available Paradym SonR Tri-V CRT-D.
|
placement of the third lead by peri-operative echo guidance.
|
Active Comparator: Standard biventricular pacing
Standard biventricular pacing (1RV/1LV) through classical implantation procedure without peri-operative optimization.
Devices used will be locally approved and commercially available Sorin implantable cardioverter defibrillators.
|
standard biventricular pacing without optimization by echo guidance
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TriV pacing is superior to standard BiV pacing in reversing ventricular modeling as demonstrated by Echo LVESV at 12 months in pts. with non LBBB without increasing the risk of serious events at 30 days.
Time Frame: 12 months
|
The efficacy endpoint for this study is the change in LVESV at twelve months post-implant between individually optimized, triple-site biventricular pacing and standard biventricular pacing. LVESV is a standard marker of CRT effectiveness1. Echocardiographic data collected at twelve months follow-up will document the evolution of LVESV as compared to baseline in order to assess reverse ventricular remodeling. The safety endpoint for this study is the rate of all serious procedure and/or device related events reported at thirty days post-implant. |
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate serious device related complications at six and twelve months post-procedure.
Time Frame: 6 and 12 months
|
A safety assessment will be performed, including all reported events collected for all enrolled patients.
|
6 and 12 months
|
Evaluate reverse ventricular remodeling response based on additional echocardiographic measures
Time Frame: 6 and 12 months
|
Change in LV volumes and LV ejection fraction will be evaluated as part of reverse remodeling response, based on echocardiographic measurements:
|
6 and 12 months
|
Evaluate patient's clinical status considering New York Heart Association (NYHA) functional class improvement
Time Frame: 6 and 12 months
|
A patient's clinical status will be evaluated considering:
|
6 and 12 months
|
Evaluate mortality and serious heart failure (HF) events during the procedure through discharge and at the different follow-up time-points.
Time Frame: 1, 6 and 12 months
|
A safety assessment will be performed, including all reported events collected for all enrolled patients.
|
1, 6 and 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jean-Claude Daubert, MD, Hôpital Pontchaillou-CHU Rennes, France
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICSY02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States